Epsilon M&A Deal Report - Diurnal Group
Transaction Multiples for the Valuation of Private Companies
Neurocrine Biosciences / Diurnal Group
No EMAT :
109861
Announced Date :
30/08/2022
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
Neurocrine Biosciences
Target :
Diurnal Group
Country :
Wales
Sector of activity :
- Health, Pharmaceuticals & Biotechnology > Biotechnology
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Founded in 2004, Diurnal Group plc is a specialty pharmaceutical company. It is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions,...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
ns | ns | ns | ns |
|
|
| Current |
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biotechnology » = 42
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 32
| Date | Acquirer | Target | Country | Multiples | See details |
| 03/12/2021 | Recordati | Eusa Pharma (UK) | England | ** | 109851 |
| 30/04/2021 | Private Group led by EW Healthcare Partners | Laboratoires Majorelle | Paris | * | 109837 |
Source: Epsilon Research / EMAT
